Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P0QG
|
||||
| Former ID |
DIB015152
|
||||
| Drug Name |
HuMV833
|
||||
| Synonyms |
Anti-VEGF antibody, Toagosei; MAb (cancer), Toagosei; SMART anti-VEGF MAb, Protein Design Labs; SMART anti-VEGF, Toagosei/PDL
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Discontinued in Phase 1 | [1] | ||
| Company |
Toagosei Co Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | VEGF receptor | Target Info | [2] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| HIF-1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012394) | ||||
| REF 2 | Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.